Pennsylvania could receive more than $14.8 million under a proposed national settlement with generic-drug manufacturers Sandoz and Fougera Pharmaceuticals.
Attorney General Dave Sunday announced the agreement Friday, saying Pennsylvania joined a coalition of states and territories in resolving claims that the companies conspired to inflate prices, reduce competition and restrain trade involving numerous generic prescription drugs.
The national settlement totals $400 million. Pennsylvania’s expected share includes as much as $9.19 million reserved for consumer restitution, according to the Attorney General’s Office. The remainder would go to state agencies.
The agreement still requires preliminary approval from the U.S. District Court for the District of Connecticut in Hartford. If approved, people who purchased certain listed generic drugs between May 2009 and December 2019 may qualify for compensation.
The Attorney General’s Office says the settlement is part of broader multistate litigation involving alleged price-fixing in the generic-drug market. Pennsylvania has participated in several related settlements and lawsuits against manufacturers accused of coordinating prices, bids or market allocation.
Eligibility will depend on the specific medication and purchase period. Consumers should retain records that may document qualifying purchases and follow official claim instructions as they become available.
The Attorney General’s Office maintains information for consumers affected by generic-drug settlements at attorneygeneral.gov. That page includes a toll-free contact number, an email address and a link to the settlement-information website.
The proposed settlement does not constitute an admission of wrongdoing. Court review will determine whether the agreement moves forward and when eligible consumers may submit claims.
